论文部分内容阅读
目的探讨美沙拉嗪片治疗溃疡性结肠炎的临床疗效及安全性。方法收集我院近3年来确诊为溃疡性结肠炎的病例75例,采用随机双盲对照设计分为治疗组(38例)、对照组(37例)。治疗组口服美沙拉嗪片1.0/次,4次/d;对照组患者口服柳氮磺胺吡啶片(SASP)1.0/次,4次/d。4周为1个疗程,治疗2个疗程后评价疗效。结果治疗组38例患者8周后显效22例、有效11例、无效5例,总有效率86.84%(33/38);对照组37例患者8周后显效14例、有效12例、无效11例,总有效率70.27%(26/37),两组的有效率有统计学差异(P<0.05)。治疗组不良反应发生率为5.26%(2/38);对照组不良反应发生率为21.62%(8/37),有统计学意义(P<0.05)。结论美沙拉嗪片对溃疡性结肠炎治疗疗效显著,且不良反应较少,安全性好。
Objective To investigate the clinical efficacy and safety of mesalamine tablets in the treatment of ulcerative colitis. Methods Seventy-five cases of ulcerative colitis were collected in our hospital in the recent 3 years. The patients were divided into treatment group (38 cases) and control group (37 cases) by randomized double-blind control design. The treatment group was given mesalazine 1.0 / time 4 times / d, while the control group was orally given SASP 1.0 / 4 times / d. 4 weeks for a course of treatment, evaluation of 2 courses of treatment efficacy. Results In the treatment group, 38 cases were markedly effective after 8 weeks, 22 cases were effective, 11 cases were effective, 5 cases were ineffective and the total effective rate was 86.84% (33/38). In the control group, 37 cases were markedly effective after 8 weeks, 14 cases were effective, 12 cases were ineffective For example, the total effective rate was 70.27% (26/37). There was a statistically significant difference between the two groups (P <0.05). The incidence of adverse reactions in the treatment group was 5.26% (2/38). The incidence of adverse reactions in the control group was 21.62% (8/37), with statistical significance (P <0.05). Conclusion Mesalazine is effective in the treatment of ulcerative colitis with less adverse reactions and good safety.